Personalis Inc. announced the commencement of commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease and recurrence in cancer.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
